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Abstract:  The renin–angiotensin–aldosterone system (RAAS) is a key mediator of blood 
pressure (BP) and volume regulation in both normotensive and hypertensive persons. 
Stimulation of RAAS also contributes to hypertension-related target organ damage. The renin–
angiotensinogen reaction is the first and rate-limiting step in the generation of angiotensin II 
(Ang II) and has been a target of antihypertensive drug development for decades. Aliskiren 
is the first in a new class of orally effective direct renin inhibitors (DRIs) and is approved for 
the treatment of hypertension in humans. It effectively reduces BP in the general population 
of hypertensive patients and has a tolerability and safety profile similar to placebo. Aliskiren 
has favorable effects on vascular inflammation and remodeling, on neurohumoral mediators of 
various forms of cardiovascular disease, including heart failure, and on proteinuria in diabetic 
patients. Additional outcome trials are needed to establish the role of this novel class of 
antihypertensive medication in preventing cardiovascular disease morbidity and mortality.
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Renin–angiotensin–aldosterone system
Blood pressure (BP) and extracellular fluid volume are regulated by the 
renin–angiotensin–aldosterone system (RAAS) in both normotensive and hypertensive 
persons. Renin is an aspartyl protease that is synthesized as a preprohormone, cleaved 
and stored in an inactive (prorenin) form in the juxtaglomerular cells surrounding 
the afferent arterioles in the kidney.1 Prorenin is rendered enzymatically active 
by both proteolytic and nonproteolytic processes. Most proteolytic activation of 
prorenin occurs within the juxtaglomerular cells by cleavage of its 43 amino acid 
N-terminal pro-segment.1 While both prorenin and active renin are secreted from 
the juxtaglomerular cells into the circulation in response to reductions in glomerular 
afferent arteriolar pressure, sympathetic nerve stimulation or reduced sodium delivery 
to the macula densa, prorenin is the predominant circulating form, accounting for 
approximately 90% of total renin in normal human plasma and for an even greater 
portion of the total in diabetic patients.2,3
Benefits of the renin–angiotensin–aldosterone 
system inhibition
Increased RAAS activity, particularly increased angiotensin (Ang) II and aldosterone 
levels, contribute to target organ damage and enhance cardiovascular risk both by 
elevating BP and through direct effects on vascular endothelium and cardiac and Therapeutics and Clinical Risk Management 2009:5 460
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renal tissues.4 Ang II promotes target organ damage through 
BP elevation and by mediating constriction and remodeling 
of resistance vessels, aldosterone synthesis and release, 
enhancement of sympathetic outflow from the brain, and 
facilitation of cathecolamine release from the adrenals and 
peripheral sympathetic nerve terminals.5,6
Various antihypertensive medications, including beta 
blockers, angiotensin-converting enzyme (ACE) inhibitors, 
Ang II receptor blockers (ARBs) and aldosterone antagonists, 
antagonize the RAAS at different steps. RAAS blockers have 
been used effectively to lower BP, limit or reverse various 
forms of target organ damage and improve outcomes in 
patients with hypertension and/or chronic kidney disease, 
coronary artery disease, left ventricular (LV) hypertrophy 
and heart failure. Direct renin inhibitors (DRIs), the newest 
class of antihypertensive agents, block the RAAS at its point 
of origin, the renin–angiotensinogen reaction, and offer a 
novel approach to the prevention or reversal of target organ 
damage and cardiovascular events.4
Aliskiren
Aliskiren is the only orally active DRI that has been approved 
for the treatment of hypertension in humans and has been 
shown to have favorable effects on target organ damage 
(Figure 1).7 Aliskiren is a competitive transition state analog 
and selective inhibitor of human renin, and has a thera-
peutic potential similar to that of other antagonists of the 
RAAS.8 In humans, the plasma concentration of aliskiren 
increases dose-dependently after oral administration in 
doses of 40–640 mg/day, peaking after 3–6 h.9 The oral 
bioavailability of aliskiren in humans is limited (2.7%) and 
the average plasma half-life is 23.7 h, ranging from 20 to 45 h, 
making aliskiren suitable for once-daily administration.9 
Aliskiren is 47% to 51% protein-bound and the steady-state 
plasma concentration is reached after 5–8 days of treatment. 
The main elimination route of aliskiren is via biliary excretion 
as unmetabolized drug.9
Although aliskiren suppresses plasma renin activity 
(PRA), it causes major reactive increases in plasma renin con-
centration. This has led some to hypothesize that reactive renin 
and prorenin secretion may limit the effectiveness of DRIs 
and can cause target organ damage independent of BP.10–12 
They reason that, if the RAAS is at all leaky, allowing even a 
small percentage of  the excess prorenin generated during DRI 
treatment to be activated, the antihypertensive effect of the 
DRI may be offset, limiting its utility as an antihypertensive 
agent. This theory is controversial and has been questioned.13 
Recently, a study carried out in transgenic mice with selective 
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Figure 1 Organs and protective effects demonstrated with aliskiren.
Abbreviations: BNP, B-type natriuretic peptide; BP, blood pressure; Cv, cardiovascular; HF, heart failure; Lv, left ventricular; Mi, myocardial infarction.Therapeutics and Clinical Risk Management 2009:5 461
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increases (13- to 66-fold) in circulating native or active 
site-mutated prorenin tested the role of prorenin in the tissue 
remodeling.14 The primary consequence of chronic eleva-
tions in circulating prorenin was high BP without associated 
increases in cardiac fibrosis or renal glomerular sclerosis.
Aliskiren in the treatment  
of hypertension
Aliskiren, both as monotherapy and in combination with 
other agents, has been evaluated extensively in hypertensive 
patients.15–17 Aliskiren monotherapy (75–300 mg/day) has a 
dose-dependent antihypertensive effect that is comparable 
to that seen with other major classes of antihypertensive 
drugs and is associated with a placebo level of side effects.18 
Comparator studies have shown that aliskiren is as effective 
as hydrochlorothiazide (HCTZ), the ARBs irbesartan, 
losartan, and valsartan, the calcium channel blocker amlo-
dipine and the beta blocker atenolol and may be slightly 
more effective than ACE inhibitors in lowering BP.2,19 
Further reductions in BP are seen when aliskiren is combined 
with antihypertensive drugs from the other major classes, 
including RAAS blockers.15 Moreover, combination of 
aliskiren with other antihypertensive agents such as diuretics 
is a useful strategy in patients who do not respond to aliski-
ren monotherapy.20 For example, in one large study that 
included almost 900 patients, a single-pill combination 
of aliskiren with HCTZ provided significantly greater BP 
reduction than aliskiren alone with similar tolerability. 
Most recently, aliskiren-based therapy (monotherapy ± 
amlodipine if needed) has been shown to be more effec-
tive than HCTZ-based therapy in reducing BP in a study of 
1124 hypertensive patients who were followed for one year.21 
Rates of adverse events and laboratory abnormalities with 
aliskiren treatment are similar to those observed with other 
RAAS blockers. Furthermore, the combination of aliskiren 
with ACE inhibitors or ARBs is safe and well tolerated.
Aliskiren in diabetic patients
The RAAS has been implicated in target organ damage in 
diabetic patients, in whom hypertension is highly prevalent 
and relatively resistant to treatment, necessitating multiple 
drug treatment in the majority of cases. The antihyper-
tensive efficacy and safety of aliskiren alone and in com-
bination with the ACE inhibitor ramipril were tested in a 
double-blind trial carried out in 837 hypertensive diabetic 
patients.22 While all therapies produced significant reduc-
tions in 24 h ambulatory BP, aliskiren monotherapy was 
superior to ramipril monotherapy in reducing systolic BP 
and noninferior in reducing diastolic BP. Importantly, the 
combination provided an additional mean BP reduction of 
4.6/2.1 mmHg over ramipril monotherapy and was well 
tolerated. These findings suggest that a DRI–ACE inhibitor 
combination provides an effective and safe therapeutic option 
for the hypertensive diabetic patient.
Aliskiren in obese patients
Pathophysiologic factors in obesity-related hypertension 
include both volume expansion and activation of  the RAAS. 
Furthermore, renin may contribute directly to obesity. Trans-
genic rats overexpressing the human renin gene have been 
shown to develop moderate obesity with increased body fat 
mass and glucose intolerance compared with nontransgenic 
Sprague–Dawley rats.23 These effects were not reversed 
by treatment with an ACE inhibitor, a DRI or a (pro)renin 
receptor blocker, suggesting that the human renin transgene, 
rather than Ang II, was responsible for the increased appe-
tite, obesity, and metabolic changes seen in this model. The 
authors point out that these mechanisms are entirely novel 
and independent of any currently known renin-mediated 
effects.
To test whether RAAS blockade is a beneficial manage-
ment strategy in obese hypertensive patients, a randomized 
double-blind study was carried out in 489 obese (average 
body mass index [BMI] 34.4 kg/m2) hypertensive patients 
that were uncontrolled on HCTZ monotherapy.24 The 
study compared the antihypertensive efficacy of aliskiren, 
irbesartan, amlodipine, and placebo-based treatment added to 
HCTZ (25 mg). After eight weeks of double-blind treatment, 
aliskiren/HCTZ produced BP reductions significantly greater 
than those seen with placebo/HCTZ and similar to those with 
irbesartan/HCTZ and amlodipine/HCTZ, with similar toler-
ability to placebo/HCTZ. Adverse event rates were highest 
with amlodipine/HCTZ because of a higher incidence of 
peripheral edema. This study demonstrates that combination 
treatment with aliskiren is an effective and well-tolerated 
therapeutic option for obese patients with hypertension who 
fail to achieve BP control with thiazide diuretic treatment, a 
growing and difficult to manage subgroup of the hypertensive 
population.
Protective effects of aliskiren
Heart
There is evidence that aliskiren reduces LV hypertrophy 
as effectively as an ARB. In the Aliskiren Left Ventricular 
Assessment of Hypertrophy (ALLAY) study, 460 over-
weight hypertensive patients were randomized to receive Therapeutics and Clinical Risk Management 2009:5 462
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aliskiren, losartan, or a combination of the two.25 Other 
antihypertensives could be added as necessary. Aliskiren 
was noninferior to losartan in reducing LV mass index, 
but the combination was not superior to losartan alone 
(Figure 2). These findings suggest that aliskiren is an effec-
tive and well-tolerated treatment option for patients with LV 
hypertrophy. The lack of additional benefit with combination 
therapy may be related to the design of the study in which 
there was no significant difference in BP reduction between 
groups. LV mass reduction seems to be directly related to 
BP reduction.
Loss of negative feedback inhibition of renin release 
during chronic treatment with ACE inhibitors leads to a 
compensatory rise in renin secretion and downstream com-
ponents of the RAAS cascade, thereby possibly attenuating 
the benefit of the treatment. Thus, it has been hypothesized 
that addition of a DRI to chronic ACE inhibitor treatment 
would benefit patients with heart failure. The Aliskiren 
Observation of Heart Failure Treatment (ALOFT) study 
tested this hypothesis in 302 patients with New York Heart 
Association class II to IV heart failure and plasma brain-type 
natriuretic peptide (BNP) concentrations 100 pg/mL who 
were being treated with a beta blocker and an ACE inhibitor 
or ARB.26 Compared with placebo treated controls, patients 
randomized to aliskiren showed significant improvement in 
neurohormonal profiles, including reductions in PRA, BNP 
and N-terminal prohormone BNP (NT-proBNP) levels, 
and in urinary aldosterone concentrations without adverse 
effects. The findings of ALOFT support further trials to 
test the safety and efficacy of aliskiren in patients with 
heart failure, either as an alternative to or in combination 
with other blockers of the RAAS. However, additional 
outcome trials are needed to support the benefit of aliskiren 
in combination with other RAAS blockers in the treatment 
of heart failure.
Kidneys
The hypothesis that aliskiren can provide renoprotection by 
reducing albuminuria in patients with diabetes was tested 
in the Aliskiren in the Evaluation of Proteinuria in Diabetes 
(AVOID) study.27 Specifically, AVOID tested whether dual 
RAAS blockade achieved by adding aliskiren to the maximal 
recommended dose of an ARB (losartan) and optimal antihy-
pertensive therapy would reduce albuminuria in 599 patients 
with hypertension, type 2 diabetes and proteinuria at baseline. 
Addition of aliskiren to ARB treatment reduced the mean 
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Figure 2 Comparison of left ventricular mass regression in patients receiving aliskiren, losartan, or their combination. Copyright © 2009,    American Heart  Association. 
Reproduced with permission from Solomon SD,   Appelbaum e, Manning   wJ, et al. effect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or 
both, on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation. 2009;119(4):530–7.
Abbreviations: Lv, left ventricular; SeM, standard error of mean.Therapeutics and Clinical Risk Management 2009:5 463
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urinary albumin-to-creatinine ratio by 20%, with a reduction 
of 50% or more in 24.7% of the patients. A nonsignificant 
2/1 mmHg difference in BP was seen between the treatment 
groups, suggesting that the renoprotective effect of aliskiren 
was independent of BP. Total numbers of adverse and serious 
adverse events were similar in both groups.
It has been suggested that DRIs may provide more 
complete and thus more effective blockade of the RAAS 
than standard recommended treatment with ACE inhibitors 
or ARBs and, therefore, may be more renoprotective. To test 
this hypothesis, the response of renal plasma flow (RPF), 
a measure of intrarenal renin activity, to treatment with 
aliskiren or an ACE inhibitor (captopril) was measured in 
20 healthy normotensive subjects whose RAAS was activated 
by consumption of a low-sodium diet.28 The RPF response 
to aliskiren was maximal at the 600 mg dose (twice the 
maximal recommended dose for hypertension treatment) 
and exceeded responses to captopril observed in this study, 
as well as responses seen previously to both ACE inhibitors 
and ARBs. Residual vasodilation was observed 48 h after 
each dose, and aliskiren treatment was associated with 
significant natriuresis. The authors concluded that DRI 
treatment provides more complete blockade of the RAAS 
than treatment with other RAAS blockers and therefore 
has potential for greater organ protection and improved 
clinical outcomes, particularly in hypertensive patients with 
concomitant cardiovascular disease.
Ongoing studies
Ongoing studies are testing whether the DRI aliskiren is 
effective in prevention or regression of various forms of target 
organ damage in humans. The Safety and Efficacy of Aliskiren 
in Post Myocardial Infarction Patients (ASPIRE) is evaluat-
ing the efficacy and safety of adding aliskiren to optimized 
standard therapy in the prevention of LV remodeling in post 
acute myocardial infarction patients.29 The Aliskiren Trial 
in Type 2 Diabetes using Cardiovascular and Renal Disease 
Endpoints (ALTITUDE) is a placebo controlled trial designed 
to determine whether adding aliskiren to conventional therapy 
reduces cardiovascular and renal morbidity and mortality 
in high risk patients with type 2 diabetes.30 ALTITUDE is 
an event driven trial that aims to randomize 8600 patients 
with type 2 diabetes who are at high risk because of 
proteinuria, microalbuminuria accompanied by a reduced 
estimated glomerular filtration rate (eGFR), or a history of 
cardiovascular disease accompanied by a reduced eGFR with 
or without microalbuminuria to aliskiren 300 mg daily or 
placebo added to usual treatment. Multiple cardiovascular 
and renal endpoints, including death are planned, and the 
expected follow-up time will be 48 months.
Conclusion
The DRI aliskiren is an effective option in the therapeutic 
armamentarium of hypertension and related target organ 
damage. Aliskiren is highly tolerable and safe and also has 
additive antihypertensive effects when combined with other 
drug classes. Preliminary studies of the effects of aliskiren 
on target organ damage such as proteinuria and heart failure 
demonstrate comparable or greater efficacy compared to 
other RAAS antagonists.
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